TransCode Therapeutics Announces Expansion of Global RNA
BOSTON, July 11. 12, 2022 (GLOBE NEWSWIRE) — TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to fighting cancer using RNA-based therapies, today announced the extension of its intellectual property portfolio by filing a provisional patent application (US 63/356,449) entitled RADIOLABELLED NANOPARTICLES AND MATRIX-DIRECTED IMMUNOMODULATION FOR THE TREATMENT OF CANCER (the ‘449 request). TransCode expects to convert the ‘449 application to an international application within about a year.
The ‘449 application aims to introduce radiotherapy in the administration of nanoparticles carrying agonist precursors based on pattern recognition receptor (PRR) RNA. Radiation therapy can be deployed for use in cancer in a systemic or targeted manner, potentially inducing tumor cells to release tumor-derived neoantigens with activation of the RIG-I signaling pathway. Once inside a tumor cell, as described in the ‘449 application and in TransCode’s preclinical testing, the nanoparticle bearing the oligonucleotide activating the selected PRR encounters a microRNA specific to that tumor, activating an induced immune response by type I interferon. The resulting immune response combined with tumor-derived antigens from radiation may have the potential to re-engage the patient’s immune system and provide synergistic therapeutic efficacy.
TransCode CEO Michael Dudley said, “We believe that by combining radiation therapy with RIG-I activation, this technology could become an important approach in how we potentially treat cancer. Activation of the RIG-I mechanism has the potential to build immunological memory and give patients’ immune systems the ability to reject tumors as if they were foreign bodies.
The ‘449 filing supports TransCode’s goals of deploying the right therapy for cancer patients. TransCode’s intellectual property portfolio includes several patent families representing issued patents, pending patent applications and new provisional patent applications. If issued, the proposed patent will join a number of other issued patents owned or licensed by TransCode, including US 9,629,812 and EP 2,961,386. As part of its overall patent strategy, TransCode is pursuing intellectual property protection for additional components of its discovery engine built around its TTX delivery platform. The TTX platform consists of a hemodynamic and metabolic tumor targeting delivery system designed to enable the deployment of a variety of RNA-based therapeutic candidates, including RNAi, pattern recognition receptors, messenger RNA, gene repair/replacement and radiolabeled therapeutics.
Dudley added, “As we focus on advancing TTX-MC138, our lead therapeutic candidate targeting microRNA-10b, in first-in-human studies, we are excited about the potential for our platform to be used more broadly in a variety of RNA approaches targeting cancer-causing genes. The approach represented by the ‘449 filing, if developed successfully, could expand our ability to deploy multimodal therapy for individual patients based on the versatility of our platform.
About TransCode Therapeutics
TransCode is an RNA oncology company founded on the belief that cancer can be defeated using RNA-based therapies. The Company is developing a platform of therapeutic candidates designed to target a variety of tumor types with the goal of significantly improving patient outcomes. The Company’s lead therapeutic candidate, TTX-MC138, is focused on the treatment of metastatic cancer, which is believed to cause approximately 90% of all cancer deaths totaling more than nine million annually worldwide. The Company believes that TTX-MC138 has the potential to produce recurrence-free regression in a range of cancers, including breast, pancreatic, ovarian and colon cancers, glioblastomas and others. Two of the Company’s other drug candidates, TTX-siPDL1 and TTX-siLIN28b, focus on treating tumors by targeting PD-L1 and Lin28b respectively. The Company is also developing other therapeutic candidates and diagnostic products related to its planned therapeutic activity.
This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding the therapeutic potential of the TTX platform and TransCode’s product candidates, including the therapeutic approach described in the ‘449 and statements regarding TransCode’s intellectual property portfolio and whether patent applications and provisional patent applications therein will be issued. All forward-looking statements contained in this press release are based on management’s current expectations regarding future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. statements. These risks and uncertainties include, but are not limited to: risk associated with drug discovery and development; the risk that the results of our planned clinical trials will not be consistent with our preclinical studies or our expectations; risks associated with the timing and outcome of TransCode’s anticipated regulatory filings; risks associated with clinical trials planned by TransCode for its product candidates; risks associated with obtaining, maintaining and protecting intellectual property; risks associated with TransCode’s ability to enforce its patents against infringers and defend its patent portfolio against challenges from third parties; the risk of competition from other companies developing products for similar uses; risks associated with TransCode’s financial condition and its need to obtain additional financing to support its business operations, including TransCode’s ability to continue as a going concern; risks associated with TransCode’s reliance on third parties; and the risks associated with the COVID-19 coronavirus. For a discussion of these risks and uncertainties, and other important factors, each of which could cause TransCode’s actual results to differ from those contained or implied by the forward-looking statements, see the section entitled “Risk Factors in TransCode’s annual report. Report on Form 10-K for the fiscal year ended December 31, 2021, together with discussions of potential risks, uncertainties and other important factors in any subsequent TransCode filings with the Securities and Exchange Commission. All information contained in this press release speaks as of the date of the release; TransCode assumes no obligation to update this information except as required by law.
For more information please contact:
TransCode Therapeutics, Inc.
Alan Freidman, Vice President of Investor Relations
Dave Gentry, CEO
Office: 1.800.RED.CHIP (733.2447)